Last $6.87 USD
Change Today +0.10 / 1.48%
Volume 220.0K
KIN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

kindred biosciences inc (KIN) Snapshot

Open
$6.86
Previous Close
$6.77
Day High
$6.96
Day Low
$6.80
52 Week High
03/14/14 - $26.99
52 Week Low
12/4/14 - $5.98
Market Cap
135.4M
Average Volume 10 Days
145.3K
EPS TTM
$-1.51
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KINDRED BIOSCIENCES INC (KIN)

Related News

No related news articles were found.

kindred biosciences inc (KIN) Related Businessweek News

View More BusinessWeek News

kindred biosciences inc (KIN) Details

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its primary small molecule product candidates include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; and SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-007, an inhibitor of Bruton’s tyrosine kinase, an enzyme important in certain lymphomas and immune-mediated human diseases; and KIND-006, a promotility agent for gastrointestinal diseases in cats. It also has a pipeline of biologic product candidates, including KIND-502, a new biologic that targets the canine counterpart of the human target for Xolair, for allergic and immune-mediated diseases; KIND-506, a new biologic that targets the canine counterpart of the human target for Enbrel, for inflammatory and autoimmune diseases; KIND-507, a new biologic that targets the canine counterpart of the human target for Orencia, for immune-mediated diseases; KIND-504, a cancer vaccine, in which the active ingredient has demonstrated efficacy in certain types of cancers in humans and in dogs, various checkpoint inhibitors, and feline erythropoietin; and KIND-501, an antiangiogenic biologic for cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

12 Employees
Last Reported Date: 04/3/14
Founded in 2012

kindred biosciences inc (KIN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $486.3K
Co-Founder, Chief Operating Officer and Secre...
Total Annual Compensation: $214.1K
Consultant
Total Annual Compensation: $95.3K
Compensation as of Fiscal Year 2013.

kindred biosciences inc (KIN) Key Developments

Kindred Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 05:00 PM

Kindred Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 05:00 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Kindred Biosciences, Inc. Announces Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Receives Approval from FDA for AtoKin's New Animal Drug Application Phase 1 CMC Technical Section

Kindred Biosciences, Inc. announced unaudited financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of USD 6,097,000 against USD 1,212,000 a year ago. Interest income was USD 25,000 against USD 2,000 a year ago. Net loss was USD 6,072,000 against USD 1,210,000 a year ago. Net loss per share, basic and diluted was USD 0.31 against USD 0.40 a year ago. For the nine months, the company reported loss from operations of USD 20,417,000 against USD 1,832,000 a year ago. Interest income was USD 67,000 against USD 2,000 a year ago. Net loss was USD 20,350,000 against USD 1,830,000 a year ago. Net loss per share, basic and diluted was USD 1.10 against USD 0.61 a year ago. The company has received approval from the FDA for AtoKin's New Animal Drug Application Phase 1 CMC Technical Section. The company has initiated several additional programs, including SentiKin for osteoarthritis in dogs, SentiKin for dental extraction, and KIND-011 for metabolic syndrome in horses. AtoKin and SentiKin programs continue to enroll rapidly and remain on track for completion in 2015. Other programs, including programs for inappetance in cats, postoperative pain in cats, KIND-012 for fever in horses, and feline erythropoeitin, continue to advance as previously planned.

Kindred Biosciences, Inc. to Report Q3, 2014 Results on Nov 13, 2014

Kindred Biosciences, Inc. announced that they will report Q3, 2014 results After-Market on Nov 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KIN:US $6.87 USD +0.10

KIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aratana Therapeutics Inc $17.49 USD +0.44
View Industry Companies
 

Industry Analysis

KIN

Industry Average

Valuation KIN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KINDRED BIOSCIENCES INC, please visit www.kindredbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.